Modulators of dopamine neurotransmission

USRE41315E1 · kind E1 · reissue

Assignee

• NSAB, Filial af NeuroSearch Sweden AB · DE

Inventors

• Clas Sonesson · Lindome, SE
• Bengt R. Andersson · Göteborg, SE
• Susanna Waters · Handen, SE
• Nicholas Waters · Handen, SE
• Joakim Tedroff · Danderyd, SE

Key dates

• Filing date: Dec 22, 2000
• Grant date: May 4, 2010
• Expiry date: Dec 22, 2020

Classification

• Technology area (CPC —): General

Abstract

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; R1 is CF3, OSO2CF3, OSO2CH3, SOR7, SO2R7, COR7, CN, OR3, NO2, CONHR3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R2 is F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, and NH2; R3 and R4 are independently H or a C1-C4 alkyl; R5 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)R6; R6 is a C3-C6 cycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; R7 is a C1-C3 alkyl, CF3, or N(R4)2, and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.